MENLO PARK, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that Gary W. Cleary, Ph.D., Pharm.D., a company co-founder, is the recipient of the 2015 Controlled Release Society ("CRS") Founders Award. The society grants this honor to a member who is internationally recognized for outstanding contributions in the science and technology of controlled release.
"We congratulate Gary on being recognized by CRS for his extraordinary contributions over a long career," said Peter D. Staple, President and Chief Executive Officer of Corium. "Gary's visionary leadership in the field of drug delivery systems and materials laid the groundwork for many important innovations in the field."
Dr. Cleary is an accomplished entrepreneur and scientist in the field of drug delivery systems and polymer technologies, having founded and co-founded companies and held management positions at many of the leading pharmaceutical companies. He was a founder of Cygnus, Inc. and Corium International, Inc. and earlier held research and management positions at ALZA Corporation, Key Pharmaceuticals and Genentech, as well as the U.S. Public Health Service and the U.S. Food and Drug Administration. Dr. Cleary was among the first researchers to determine and investigate the development of drug delivery systems for large molecular weight biomolecules. Over the past 40 years he has been the author and co-author of numerous publications and books addressing innovation in transdermal drug delivery technologies, applications and product research and development. Dr. Cleary holds more than 50 patents covering a range of scientific research and applications in the field including transdermal, polymer and permeation technologies. He has been the recipient of multiple industry awards and honors including entrepreneur of the year awards from Life Sciences for Northern California, New Jersey Center for Biomaterials and the AAPS Rainer Hoffman Award, in addition to the UCSF Distinguished Alumnus Award. Dr. Cleary earned a Pharm.D. from the University of California, San Francisco, a, Ph.D. from Rutgers University and a MBA from University of Miami.
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders. For further information, please visit www.coriumgroup.com.
CONTACT: Investor and Media Contact: Karen L. Bergman BCC Partners email@example.com 650-575-1509
Source:Corium International, Inc.